UroCor, Oklahoma City - Mallinckrodt will sell and distribute its new radiation treatment for prostate cancer - Company Business and Marketing - Brief Article

Health Industry Today, Nov, 1999

UroCor, Oklahoma City, has entered into an agreement with Mallinckrodt, Inc., St. Louis, by which Mallinckrodt will sell and distribute UroCor's new radiation treatment for prostate cancer through Mallinckrodt's 35 nuclear medicine pharmacies and more than 80 independent pharmacies. Mallinckrodt will also add the products to its group-purchasing contracts with hospital groups such as premier. The agreement is said to broaden Mallinckrodt's produce offering in nuclear medical while providing UroCor with an instant presence in the radiation oncology market. The UroCor product, ProstataSeed I-125, has received 501(k) clearance for marketing in the U.S. and is awaiting final approval from the Nuclear Regulatory Commission. UroCor expects product launch to occur later this year following regulatory clearance by the NRC, at which time the Mallinckrodt agreement will become effective.

* wwurocor.com www.mallinckrodt.com